Supplementary Table 2. Subgroup analyses of 68Ga-PSMA-11 PET/CT SUVmax in patients with or without adverse pathology.
| Factors | Variable | 68Ga-PSMA-11 PET/CT SUVmax | Pa value | |
|---|---|---|---|---|
| Without adverse pathology* | With adverse pathology | |||
| Age (y) | ≤ 57 | 14.57(8.25-26.89) | 32.03(28.19-34.39) | <0.001 |
| > 57 | 14.39(6.43-19.24) | 29.98(27.87-32.54) | <0.001 | |
| Sex | Male | 13.83(6.26-19.12) | 31.55(28.19-33.47) | <0.001 |
| Female | 17.01(8.91-26.81) | 31.00(26.18-34.39) | 0.008 | |
| Tumor location | Left | 13.99(6.43-19.55) | 32.54(29.45-35.33) | <0.001 |
| Right | 14.94(8.25-23.32) | 29.19(25.78-32.03) | 0.002 | |
| Tumor maximal diameter (cm) | ≤ 6.7 | 11.49(6.71-14.99) | 30.51(26.18-32.03) | <0.001 |
| > 6.7 | 20.44(7.58-26.93) | 33.47(29.45-35.33) | 0.001 | |
| Tumor stage | T1-T2 | 10.39(6.26-17.39) | 26.18(25.31-28.19) | <0.001 |
| T3-T4 | 23.52(14.94-34.97) | 33.00(30.64-35.33) | 0.003 | |
| WHO/ISUP grade | 01-Feb | 10.39(6.26-14.99) | 27.03(25.31-29.45) | 0.001 |
| 03-Apr | 26.93(23.52-32.98) | 33.47(31.55-35.33) | 0.015 | |
*
Adverse pathology is defined as tumor presenting with necrosis or a sarcomatoid or rhabdoid feature
a
P values were calculated with Mann-Whitney U test
SUVmax = maximum standardized uptake value; WHO/ISUP = World Health Organization / International Society of Urological Pathology
Data are median (interquartile range) for SUVmax